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ABSTRACT 
Inflammatory bowel diseases (IBD) are emerging globally, indicating that environmental factors 
may be important in their pathogenesis. Colonic mucosal epigenetic processes, such as DNA 
methylation, can respond to environment, and have been implicated in IBD pathology. However, 
mucosal DNA methylation has not been examined in treatment naïve patients.  We studied DNA 
methylation from untreated, left sided colonic biopsy specimens by Infinium 
HumanMethylation450 BeadChip Kits in 22 control [C], 15 untreated Crohn’s disease [CD], and 
9 untreated ulcerative colitis [UC] patients from two cohorts. Samples at the time of clinical 
remission from two of the treatment naïve UC patients were also included into the analysis. UC 
specific gene expression was interrogated in a subset (5 C and 5 UC) of adjacent samples by 
Affymetrix GeneChip PrimeView Human Gene Expression Arrays. Only treatment naïve UC 
separated from control. One hundred and twenty genes with significant expression (>2 fold, 
p<0.05) change in UC associated with differentially methylated regions (DMR’s). The 
epigenetically associated gene expression changes (including IFITM1, ITGB2, S100A9, SLPI, 
SAA1, and STAT3) linked to colonic mucosal immune and defense responses. These findings 
underscore the epigenetic relationships of inflammation in pediatric treatment naïve UC and 
may have potential etiologic, diagnostic, and therapeutic relevance for IBD. 
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INTRODUCTION 
Inflammatory bowel diseases (IBD), including Crohn disease (CD) and ulcerative colitis 
(UC), are emerging globally.1 IBD is associated with high morbidity, leading to a significant 
health care burden.2 The incidence of IBD peaks in young adulthood, and cases are becoming 
more common, especially in the pediatric population.3-5 The increased number of pediatric 
cases appear to result from an overall amplified incidence rather than a shift toward disease 
onset at younger age.6  About 20% of IBD presents in children,7-9 where the diseases usually 
carry a more aggressive phenotype than in adults.10 
While the cause or causes of IBD remain to be identified, dietary and environmental 
changes in the industrialized world have been proposed as possible etiologic factors. Such 
factors may impose critical alterations in the key physiologic components of IBD pathogenesis 
during prenatal and/or pediatric development.11, 12 One molecular process that can dynamically 
respond to nutritional changes in the gut mucosa is DNA methylation.13 DNA methylation is an 
epigenetic change occurring at cytosines in CpG dinucleotides and plays an important role in 
gene expression regulation. Epigenetic maturation relevant for intestinal immune regulation 
continues beyond infancy in mammals, indicating that even postnatally occurring DNA 
methylation changes may be important in IBD pathogenesis.14 Furthermore, maternal 
micronutrient supplementation can induce colonic mucosal DNA methylation modification 
relevant for murine colitis susceptibility, implicating this epigenetic process in the developmental 
origins of IBD.13, 15 
 Differentially methylated CpG sites in inflamed intestinal tissues of IBD patients have 
been detected with limited (1,505 methylation sites interrogated) molecular screens16 supporting 
this epigenetic change as a potential etiologic component in IBD. Metabolite profiling also 
supported the role of DNA methylation in mammalian mucosal inflammation.17 A functional 
methylome map of UC was recently laid out based on colonic mucosal samples from adult 
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discordant monozygotic twin pairs.18 However, none of the prior studies examined treatment 
naïve, or pediatric samples. In the meantime, immuno-therapy and long standing disease may 
complicate the identification of pathogenic DNA methylome changes in IBD.  Additionally, 
secondary to its more aggressive course, pediatric IBD may carry unique molecular 
characteristics compared to adult. Therefore, we set out to explore DNA methylation and gene 
expression associations of pediatric IBD in the colonic mucosa of untreated children.  
 
RESULTS 
Mucosal DNA Methylation Separates in Treatment Naïve Pediatric Ulcerative Colitis  
 Overall methylation variation between combined treatment naïve samples and 2 treated 
UC samples was examined by correlation based principal component analysis (PCA). There 
was no consistent separation within the discovery and validation samples when CD cases were 
compared to controls (Figure 1).  On the contrary, all treatment naïve UC mucosal samples 
segregated distinctly from controls by DNA methylation driven PCA in one dimension of the 3 
dimensional PCA (Figure 1, upper panel). Interestingly, in the same dimension, there was a 
gender based separation between the samples as well. Nevertheless, treatment naïve UC 
mucosal DNA methylomes separated from controls both in the female and male groups. 
Importantly, this separation was lost in the 2 males examined (grey arrows, Figure 1, upper 
panel) upon treatment with infliximab or 6-mercaptopurine, respectively, which induced clinical 
remission in both patients according to the pediatric ulcerative colitis activity index (PUCAI19). 
 
Differentially Methylated Regions in Pediatric Colonic IBD Mucosa 
Regional DNA methylation variation may be more important in the regulation of gene 
expression than single CpG site specific ones. Therefore, we performed bump-hunter analysis20 
to identify differentially methylated regions (DMRs) in pediatric IBD colonic mucosa compared to 
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controls. We included the treated samples into the analysis to decrease the inevitable bias 
induced by inflammation as shown in the section above. We chose an arbitrary p value cut-off of 
p<10-4. By this means, we found 182 CD associated (Table S2), and 3,365 UC associated 
DMRs (Table S3). These DMRs linked to 108 CD associated, and 2243 UC associated genes, 
respectively. Fifty-eight (53.7%) of the CD associated genes with DMR links overlapped with the 
UC associated genes with DMRs. This finding indicated that a large portion of the IBD 
associated mucosal epigenetic changes overlap and that those may arise from non-specific 
inflammation, which may be more pronounced in face of the confluent colitis characteristic of 
UC.    
   
Mucosal Epigenetic Changes in UC Associate with Immune and Defense Responses 
Gene expression was interrogated by microarrays in a subset (5 C and 5 UC) of the 
patients from adjacent biopsy samples to examine the direct functional relevance of the UC 
specific regional DNA methylation changes. There were 809 genes with increased (>2 fold, 
p<0.05) expression (Table S4), and 353 with decreased expression in UC mucosa compared to 
control (Table S5). Ninety five (11.7%) of the genes with increased expression had UC linked 
DMR associations (Table S6). Twenty five (7.01%) of the genes with decreased expression had 
UC linked DMR associations (Table S7). 
There was no significant enrichment of biological processes among the genes with 
decreased expression that had DMR associations, compared to the rest of the genome. On the 
contrary, immune response, defense response, antigen processing and presentation of peptide 
antigen, antigen processing and presentation, MHC class I peptide loading complex, and MHC 
protein complex were significantly (corrected p<0.05) enriched among the genes with increased 
expression that had DMR association.  
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DISCUSSION   
This study includes the most in depth Infinium Methylation Array based interrogation of 
intestinal mucosal samples in IBD and is the first to examine pediatric cases. Yet, the peak 
incidence of IBD in young adulthood suggests that epigenetic changes occurring during 
childhood may be important in the etiology of these disorders.14 Furthermore, the limited length 
of disease and the usual absence of co-morbid conditions at the onset of pediatric IBD present 
a unique opportunity to examine dynamic molecular processes, such as epigenetic changes, in 
respect to the developmental origins of the disease group.21 
Our findings indicate that DNA methylation changes in the transverse colonic mucosa 
are more prominent and therefore lead to a more significant separation in pediatric UC than in 
CD, compared to controls.  
  The recently developed methylation microarray employed herein has been validated in 
normal adult colonic mucosa and colorectal cancer cell lines.22 Our validation (Figure S1) also 
supports the reliability of this microarray in human colonic mucosal studies. Although we 
examined small cohorts, the independent interrogation of discovery and validation sets with in-
depth genomic microarrays (482,421 CpGs interrogated) and the combined analysis of those 
provided significant strength to our results. Additionally, the treatment naïve nature of the 
samples examined is unique compared to any other epigenomic study on mucosal DNA in 
relationship to IBD thus far. Geographical bias can also complicate multi-center studies on 
flexible biological systems involved in IBD pathogenesis.23 Our validation cohort contained 
samples from a single center to address this potential confounding factor as well. 
There was a remarkable colonic mucosal epigenetic separation of UC compared to CD 
(Figure 1). This separation may in part be linked to the clinically less diverse nature of UC. 
Furthermore, the more prominent UC clustering may have resulted from a more intense and 
confluent inflammation that frequently characterizes the disease, compared to CD. This 
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predicament is supported by the fact that the two biopsy samples from treated patients (in 
clinical remission) clustered together with controls, as opposed to their treatment naïve 
counterparts (Figure 1 grey arrows). The finding for loss of colonic mucosal DNA methylome 
separation upon conventional treatment of UC is the most important observation in this work. 
This result indicates that the vast majority of the DNA methylation changes identified were 
secondary to the inflammatory process of UC and that those are not persistent when the 
severity of the disease declines.  
Over 50% of the CD associated DMRs were identified in UC mucosa as well. This 
finding also supports our conclusion that a large portion of the colonic mucosal epigenetic 
modifications in pediatric IBD arise from non-specific inflammatory changes. Our study was not 
powered to enable the determination whether disease specific DNA methylation differences 
exist in treatment naïve colonic mucosa, or not. Whether the DNA methylome can differentiate 
UC from CD will require the examination of much larger sample sizes of the two major IBD 
classes. Although obtaining mucosal biopsies is more invasive than stool collection or 
phlebotomy, colonoscopy is generally performed to confirm the diagnosis of IBD. Sampling for 
DNA methylation based differential diagnostic purposes could take place during this procedure. 
DNA methylation in more readily available cells such as peripheral blood leukocytes (PBL) did 
not differentiate between UC and CD in treatment naïve children with the same arrays as 
utilized in this study.24 This may be secondary to the need for cell type based fractionation of 
PBLs prior to DNA methylation interrogation,25, 26 since epigenetic patterns are cell and tissue 
specific.  Similarly, mucosal cell sub-fractionation from colonic biopsy specimens27 may further 
our understanding of IBD-epigenome relationships. However, sub-fractionation required pooled 
biopsy samples to generate sufficient DNA material for high-throughput analyses, limiting its 
clinical feasibility. Cell sub-fractionation may also result in the potential loss of critical epigenetic 
information, which question requires further analyses in the future.  
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The associations between DNA methylation and gene expression delineated in this 
study highlight the functional relevance of the UC specific epigenetic changes identified. There 
was a significantly increased expression of genes involved in immune and defense responses in 
association with the DNA methylome of treatment naïve UC. This result highlights the 
importance of epigenetic mechanisms in the regulation of the inflammatory cascade 
characteristic for UC.  
Among the genes with UC specific increased expression in association with DNA 
methylation changes, S100 calcium binding protein A9 (S100A9) has already been found with 
increased expression in both CD and UC colonic mucosa.28 In agreement with our results, other 
investigations outside of the GI tract on S100A9 have shown its increased expression upon 
treatment with 5-aza-2’-deoxycitidine, and inhibitor of DNA methyltransferase 1 (DNMT1).29 
Similar to our findings, secretory leukocyte peptidase inhibitor (SLPI) expression was increased 
selectively in UC mucosa (not in CD) that appeared to originate from mucosal inflammatory 
cells.30 This later work indicates that some of the gene expression signals detected in this study 
may have derived from mucosal immune cells rather than epithelial, albeit specific to UC. 
Another important result is the increased expression of STAT3 in the colonic mucosa of 
treatment naïve UC patients in association with decreased gene body methylation overlapping 2 
exons (Supplementary Table 6). The importance of the STAT3 signaling pathway has been 
highlighted in pediatric onset UC, where increased expression of the gene was noted in the 
colonic mucosa,31 similar to our findings. Inverse correlation between gene methylation and 
expression of STAT3 has been recently demonstrated,32 supporting our results, which indicate 
that epigenetic changes may be an important element in the regulation of the STAT3 signaling 
pathway. Further publications demonstrate the reliability and value of our findings on 
inflammation associated increased expression of SAA1,33 IFITM1 and ITGB234 in UC, for 
example.  
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  This work includes the first high-throughput DNA methylation and gene expression 
association study on IBD from treatment naïve colonic mucosal samples. The results indicate 
the potential importance of epigenetic mechanisms in the modulation of the inflammatory 
changes characteristic of UC. We also conclude that the large majority of the DNA methylation 
and gene expression changes at the diagnosis of the disease are transient and respond to 
treatments/disease remission. Further work towards deciphering the contribution of different cell 
types to the findings of this study performed on whole mucosal biopsies is needed. Our findings 
may promote the establishment of DNA methylation based differential diagnostic and 
therapeutic modalities for pediatric UC. 
 
PATIENTS AND METHODS 
Patients and Samples. Secondary to the dynamic nature of epigenetic changes, the following 
factors were controlled: age, gender, colonic location,35, 36 and treatment status.37 Hence, only 
treatment-naïve patients and controls were examined.  Discovery (10 controls [C], 10 Crohn 
disease [CD], and 4 ulcerative colitis [UC]) and validation cohorts (12 C, 5 CD, 5 UC) of patients 
were included (Table 1 and 2). Control patients in the discovery cohort were recruited prior to 
endoscopy through the pediatric gastroenterology tissue bank of the Pediatric Inflammatory 
Bowel Disease Consortium Registry of the Baylor College of Medicine (BCM), Charles 
University, Prague, Czech Republic, and MassGeneral Hospital for Children, which were 
established in agreement with local and federal regulations.  Only patients with grossly and 
histologically normal mucosa at colonoscopy were designated as controls. Treatment naïve IBD 
cases in the discovery cohort were recruited prior to their first diagnostic colonoscopy in the 
latter two locations and their disease was determined based upon clinical, biochemical and 
histological characteristics. The validation cohort patients were all enrolled at BCM to eliminate 
potential center bias. Left sided (from mid transverse to rectal) colonic mucosal samples were 
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snap frozen on dry ice or in liquid nitrogen immediately after biopsy and stored at -80oC until 
further analysis. The inflammatory cell infiltration in the adjacent transverse colon biopsies of 
UC patients was rated between mild to severe on a numeric scale by a blinded pathologist. 
Treated samples from one patient each (Table 1*) from the two cohorts were also included into 
the analyses to examine and decrease inflammation bias.  
 
DNA Extraction. After thawing, the colonic mucosal biopsies of the discovery cohort were 
centrifuged at 14,000 rpm for 30 seconds and resuspended in 500µl RLT buffer (Qiagen, 
Valencia, CA) (with β- mercaptoethanol). Sterile 5mm steel beads (Qiagen, Valencia, CA) and 
500µl sterile 0.1mm glass beads (Scientific Industries, Inc., NY, USA) were added for complete 
bacterial lyses in a Qiagen TissueLyser (Qiagen, Valencia, CA), run at 30Hz for 5min. Samples 
were centrifuged briefly and 100µl of 100% ethanol added to a 100µl aliquot of the sample 
supernatant. This mixture was added to a DNA spin column, and DNA recovery protocols were 
followed as instructed in the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) starting at step 5 of 
the Tissue Protocol. DNA was eluted from the column with 30µl water and samples were diluted 
accordingly to a final concentration of 20ng/µl. As for the discovery cohort, genomic DNA was 
isolated by standard proteinase-k digestion and phenol-chloroform extraction and bisulfite 
converted as described previously.38  This approach eliminated potential DNA extraction method 
based bias. DNA concentrations were determined by a Nanodrop spectrophotometer (Nyxor 
Biotech, Paris, France). 
 
RNA Extraction and Processing for Microarrays. Colonic mucosal RNA was isolated by 
Qiangen-Qiazol - miRNA Isolation Kit. cDNA amplification and labeling was performed with 
Ovation Pico WTA System V2 and Encore Biotin Module (NuGEN), respectively. Array 
hybridization was performed according to Affymetrix FS450_0002 Hybridization Protocol for 
11 
 
gene expression. The Affymetrix GeneChip® PrimeView™ Human Gene Expression Arrays 
were scanned with Affymetrix Genechip Scanner 7G.  
 
Infinium Methylation Assay Microarrays. The transverse colonic mucosal DNA sample 
quality was examined with PicoGreen (http://probes.invitrogen.com/media/pis/mp07581.pdf) 
before processing towards the microarrays. The samples that passed quality control were 
processed by Infinium HumanMethylation450 BeadChip Kits (Illumina San Diego, CA, USA; 
http://www.illumina.com/products/methylation_450_beadchip_kits.ilmn) according to the 
manufacturer’s recommendations through automated processes in the Core Laboratory for 
Translational Genomics of the Baylor College of Medicine.  Arrays were imaged with BeadArray 
Reader using standard Illumina scanner settings. The R Bioconductor minifi package39 was 
used to generate beta values normalized to internal control probes. Internal controls determined 
the array processing to be of good quality. After removal of probes containing SNPs 
(http://www.rforge.net/IMA/snpsites.txt), 390,433 CpG probes on the array were used for 
subsequent analysis. The R Linear Models for Microarray Data (Limma) package40 was used to 
compare beta values and identify differentially methylated probes between controls and CD, or 
UC affected individuals. Limma fitted a linear model to beta values for each probe in the 
compared samples and then calculated a t-statistic using an empirical Bayesian model that 
moderates the standard errors across probes. P-values were calculated from the moderated t-
statistics and multiple testing correction of the p-values was performed using Benjamini and 
Hochberg’s method41 (false discovery rate: FDR) to identify differentially methylated probes. The 
R Bioconductor bumphunter package was used for identifying differentially methylated regions. 
The R prcomp function was used to perform principal component analysis (PCA) based on beta 
values for the samples. The raw data of the microarrays was uploaded to Gene Expression 
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Omnibus (GEO; Series GSE32146) and is accessible at:  Discovery cohort: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=frutfkgmamamkvi&acc=GSE32146.  
Validation cohort: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=pvojjiqcqiuqori&acc=GSE42921. 
 
Bisulfite Pyrosequencing Validation. Colonic mucosal DNA from the discovery cohort was 
bisulfite converted with EZ DNA Methylation-Gold Kit (D5006, Zymo Research, Orange, CA, 
USA). DNA was amplified with traditional primer biotinylation following bisulfite conversion. A 
quantitative bisulfite pyrosequencing protocol was used for all methylation analyses with the 
utilization of the Pyro Q CpG program (QIAGEN GmbH, QIAGEN Strasse 1. 40724 Hilden, 
Germany). Infinum array validation was performed at 5 candidate loci with corrected p<0.01 in 
the discovery cohort: (SMAD3 associated: chr15:67442893-67442893; C8orf74 associated: 
chr8:10555466-10555466; FLT1 associated: chr13:28975690-28975690; “Chr1”: 
chr1:120289923-120289923 and “Achr1”: chr1:150535935-150535935). Table S1 shows the 
pyrosequencing primers utilized for the validation.  
Bisulfite pyrosequencing at 5 independent loci correlated significantly with the 
microarrays of the discovery cohort (r=0.87, p<0.0001; Figure S1) supporting the reliability of 
the results. Table S1 shows the pyrosequencing primers utilized for the validation of the 
discovery microarrays. 
 
Gene Expression Microarray Analysis. The R Bioconductor affy package42_ENREF_43 RMA 
(robust multi-array average) function was used to compute expression. The CEL files and RMA 
normalized expression values can be downloaded from 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=pzyffweqggmsgnk&acc=GSE42911. 
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Affymetrix GeneChip PrimeView Human Gene Expression Array probe annotations were 
associated with Infinium HumanMethylation450 v1.1 probe annotations based on gene symbols. 
The beta values of Infinium probes showing differential methylation between UC and control 
samples were compared to the averaged RMA values for genes with multiple probe sets based 
on the gene symbol association.  
 
Statistical and Bioinformatic Analysis. Unpaired, two tailed, t-test; was used in the group 
comparisons. Statistical significance was declared at p<0.05. DAVID 
(http://david.abcc.ncifcrf.gov/) was utilized to examine gene ontology enrichment in the select 
gene lists; significance was declared at P values adjusted for multiple testing p<0.05.  
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FIGURE LEGENDS 
 
Figure 1 Principal component analysis (PCoA) of DNA methylation. CD: Crohn disease; 
Ctrl: Control; UC: ulcerative colitis. The ulcerative colitis DNA methylome separated in one 
dimension from controls both in males and females (upper panel). Interestingly, males and 
females separated from each other regardless of disease status in this dimension. The UC 
specific separation was lost upon treatment induced clinical remission in 2 of the male patients 
studied (grey arrows). There was no obvious disease specific separation in the other 
dimensions of the analysis (middle and lower panels). 
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Age 
(y) 
G R Diagnosis  Cohorts 
Age 
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G R Diagnosis 
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C 3.5 M W Juvenile polyp   
V
a
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o
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o
rt
 
C 11 F H Abdominal pain 
C 15 F W Hematochezia  C 17 M H Diarrhea, weight loss 
C 17 M W Perianal fissure  C 15 M W Abdominal pain 
C 17 F W Abdominal pain  C 17 M AA Abdominal pain 
C 17 F W IBS  C 14 F W Abdominal pain 
C 17.5 F W Healthy  C 15 F W Abdominal pain 
C 8 F W Hematochezia  C 16 F W Diarrhea 
C 12 M W Diarrhea  C 16 F W Abdominal pain 
C 13 M W Abdominal pain  C 15 F W Abdominal pain 
C 10 M W Abdominal pain  C 16 F W Hematochezia 
        Montreal classification  C 15 M W Abdominal pain, hematochezia 
        Age Location Behavior   C 9 F W Abdominal pain, hematochezia 
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CD 16 M W A2 L3 B1           Montreal classification 
CD 17 M W A2 L3 B1           Age Location Behavior 
CD 15 M W A1 L3 L4 B1   CD 6 F W A1 L3 L4 B1 
CD 8 F W A1 L3 L4 B1   CD 11 M A A1 L2 B1 
CD 16.5 F W A2 L3 L4 B1   CD 11 M W A1 L2 L4 B2 
CD 13 F W A1 L3 L4 B1   CD 19 F AA A2 L2 B2 
CD 8 F W A1 L2 L4 B1   CD 16 F H A2 L2 B1 
CD 15.5 F AA A2 L3 L4 B1           Montreal classification of extent 
of UC CD 17.5 M W A2 L3 L4 B1           
CD 13 F na A1 L2 B2   UC 12 F W E3 
        Montreal classification of 
extent of UC 
 UC 11 M AA E3 
          *UC 16 M W E3 
UC 10 F W E3   UC 13 F AA E3 
UC 15 F W E3   UC 5 F H E3 
UC 19 M na E2           
*UC 13 M W E3          
Table 1. Demographics and disease characteristics of the discovery and validation cohorts. A 
(y):Age (years); A:Asian; AA:African American; B:Behavior, C:Control; CD:Crohn Disease; 
E:Extent; F:Female; G:Gender; H:Hispanic; L:Location; M:Male; na:non-applicable; R:Race; UC: 
Ulcerative Colitis; W:White. * indicates patients whose post-treatment samples were also 
interrogated 
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Cohorts Diagnosis 
Age (years) Gender 
Mean  Median Min to Max (M;F) 
Discovery Cohort 
(n=24) 
C 13.0 14.0 3.5-17.5 5;5 
CD 14 15 8-17.5 4;6 
UC 14 14 10-19 2;2 
Validation Cohort 
(n=22) 
C 14.67 15.0 9-17 4;8 
CD 12.6 11.0 6-19 2;3 
UC 11.4 12.0 5-16 2;3 
Table 2. Summary of cohort groups including the diagnosis, age and gender of the patients in 
this study. C:Control; CD:Crohn Disease; F:Female; M:Male; UC: Ulcerative Colitis. 
 
 
 
 
 
 
 
 
 
 
 
